Profile photo Peter van de Ven

Peter van de Ven

Associate Professor

Strategic program(s):

Biography

I am an associate professor in clinical trial methodology and statistics working within the Department of Data Science and Biostatistics of the Julius Center where I lead the Clinical Trial Methodology & Statistical Consultation team. My interests lie in innovative clinical trial methodology (both development and application) and adaptive methods, trials-within cohorts and trials in rare diseases in particular. I am the Trial Methodology Lead for U-TRIAL and workpackage leader for the Adaptive Trial Platform WP in the ONCODE-ACCELERATOR growthfund project. I am the chair of the UMC Utrecht's internal DSMB.  I also act as a methodology assessor (seconded) for the Dutch Medicines Evaluation Board (College ter Beoordeling van Geneesmiddelen: CBG-MEB). 

From July 2009 until April 2021 I worked at the Amsterdam UMC location VUmc as a researcher, a statistical consultant and methodology member of the hospital's institutional review board (METc).

I hold a PhD degree in Statistics from Eindhoven University of Technology (2007), a M.A. degree in Health Psychology from Tilburg University (2003) and a M.Sc. degree in Engineering Mathematics from Eindhoven University of Technology (2001). I have held postdoctoral research positions at the Southampton Statistical Sciences Research Institute S3RI (2007-2008) and TNO Quality of Life (2008-2009).

Strategic program(s):

Contact

Research groups

Julius Center Research Program Cancer

Research aim

Our mission is to drive impactful innovation for cancer prevention, diagnosis, prognosis, treatment, and care through interdisciplinary research, fostering collaboration among researchers across disciplines within the Julius Center and beyond.
Go to group

Clinical trial methodology & statistical consultation

Research aim

We develop, evaluate, and apply innovative clinical trial designs and sound statistical methodology to efficiently obtain high-quality evidence on healthcare interventions, ultimately optimizing patient outcomes
Go to group

Recent publications

Breaking the chains of lipoprotein lipase deficiency Bibiche den Hollander, Marion M. Brands, Ilse J.M. Nijhuis, Lous J.A.E. Doude van Troostwijk, Peter van Essen, Ageeth H. Hofsteenge, Bart G. Koot, Annelieke R. Müller, Laura A. Tseng, Erik S.G. Stroes, Peter M. van de Ven, Albert Wiegman, Clara D.M. van Karnebeek
Molecular Genetics and Metabolism, 2024, vol. 142
Hyperbaric Oxygen Therapy and Late Local Toxic Effects in Patients With Irradiated Breast Cancer Dieuwke R Mink van der Molen, Marilot C T Batenburg, Wiesje Maarse, Desiree H J G van den Bongard, Annemiek Doeksen, Marjoleine Y de Lange, Carmen C van der Pol, Daniel J Evers, Corine A Lansdorp, Jacco van der Laan, Peter M van de Ven, Femke van der Leij, Helena M Verkooijen
JAMA Oncology, 2024, vol. 10, p.464-474
The multiple mediating effects of vision-specific factors and depression on the association between visual impairment severity and fatigue Wouter Schakel, Christina Bode, Peter M. van de Ven, Hilde P.A. van der Aa, Carel T.J. Hulshof, Gerardus H.M.B. van Rens, Ruth M.A. van Nispen
BMC Psychiatry, 2024, vol. 24
Corrigendum to “Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation Bibiche den Hollander, Marieke Rothuizen-Lindenschot, Lisa Geertjens, Frédéric M. Vaz, Marion M. Brands, Hoang Lan Le, Agnies M. van Eeghen, Peter M. van de Ven, Martina C. Cornel, Bart A.W. Jacobs, Hilgo Bruining, Clara D. van Karnebeek
Contemporary Clinical Trials Communications, 2024, vol. 38
Rationale and design for the randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel/acetylsalicylic acid) on the occurrence of atherothrombotic events Emilien C.J. Wegerif, Çağdaş Ünlü, Manon I. Generaal, Rutger M. van den Bor, Peter M. van de Ven, Michiel L. Bots, Gert J. de Borst
American Heart Journal, 2024, vol. 273, p.121-129
Tailored guidance to apply the Estimand framework to Trials within Cohorts (TwiCs) studies R. Gal, R. Kessels, K. Luijken, L. A. Daamen, D. R. Mink van der Molen, S. A.M. Gernaat, A. M. May, H. M. Verkooijen, P. M. van de Ven
Global Epidemiology, 2024, vol. 8

External positions

Member of review committees Development (since January 2022) and PIPELINE (since April 2024) - Reviewer of grant applications submitted to Dutch Cancer Society (KWF) - KWF

Expert statistical reviewer - Performing statistical reviews of manuscripts submitted to Diabetologia journal - Diabetologia

Methodology assessor - Assessing dossiers filed for marketing authorization application and providing scientific advice - Dutch Medicines Evaluation Board (CBG-MEB)